Thu, Jul 31, 2014, 10:31 AM EDT - U.S. Markets close in 5 hrs 29 mins

Recent

% | $
Click the to save as a favorite.

Advanced Cell Technology Inc. Message Board

  • hwmccusker hwmccusker Mar 8, 2013 8:43 AM Flag

    The whirling dervish of Regmed - Q4 and FY12 results

    The Bottom Line: ACTC – the “whirling dervish” of companies – has announced promising data from its most advanced clinical programs in AMD and SMD and made solid progress in clinical trials. However, losses continue to increase … reported a Q4/12 loss from operations of $6.2 M compared to a loss from operations of $5.8 M in the Q4/11. For FY12, ACTC reported a loss from operations of $21.1 M compared to a loss of $21.1 M a year before. At least the Q4/12 net loss decreased incrementally . Also, the net loss decreased year to year of $28.5 M versus $72.8 M. Love the ego driven CEO conference call comments … “I used to not answer my phone because it was always somebody we owed money to. Now I don’t answer it because it’s always somebody who wants to invest in the company”. With issued – 2.232 B and outstanding shares of 1.743 B and an $8.496 B shareholder deficit and total liabilities– no wonder Rabin won’t take investors calls. Can anyone take responsibility to make ACTC a real company – that has good science, growing and even glowing trial results! ACTC closed at $0.07 on 3/7/13 – moving from $0.08 since 2/20/13 and $0.09 on 1/29/13.

    Sentiment: Sell

 
ACTC
0.0651-0.0004(-0.61%)10:11 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.